RORα, short for retinoic acid receptor-related orphan receptor alpha, is a transcription factor that senses cholesterol levels and switches genes on or off in response. Genetic variants of the RORA gene have previously been associated with increased susceptibility to both the dry and neovascular forms of AMD in humans, and earlier work from the same group showed that RORα deficiency worsens laser-induced choroidal neovascularization in young mice. What remained unclear was exactly how the receptor influences the immune cells that swarm into the aging retina and whether its effects on fat metabolism and inflammation were two sides of the same coin. The new study set out to answer that question using two complementary mouse models: the spontaneous Staggerer mutant (Rora sg/sg), which lacks functional RORα throughout the body, and a myeloid-specific knockout (Rora fl/fl;LysMCre) in which the receptor is deleted only in macrophages and related immune cells.

The results were striking. As the Staggerer mice aged, they developed increasing numbers of abnormal whitish-yellow fundus lesions that resemble the drusen and deposits seen in human AMD patients, with more than a fivefold increase in lesion number by nine months of age. Retinal cross-sections revealed subretinal deposits, focal disruption of the retinal pigment epithelium, and sloughed RPE cells. Critically, the subretinal space of these mice, which in healthy eyes is normally kept free of immune cells by immunosuppressive factors secreted by the RPE, became crowded with CD11b- and IBA1-positive microglia and macrophages. The counts were more than double those of age-matched controls, and the accumulated immune cells were visibly bloated with neutral lipids, stained with a fluorescent lipid probe called LipidSpot 610. The number of these lipid-laden cells correlated with the density of fundus lesions, suggesting a causal relationship between immune cell fat overload and the visible pathology.

When the researchers induced choroidal neovascularization with laser photocoagulation in aged mice, the Staggerer animals fared far worse than controls. Their CNV lesions were significantly larger, surrounded by expanded zones of IBA1-positive macrophages and microglia, and far leakier on fluorescein angiography. While roughly 43 percent of lesions in wild-type aged mice showed only mild grade 1 hyperfluorescence and none reached the pathologically significant grade 2B, the RORα-deficient mice showed a much higher proportion of severely leaking lesions. Even outside the laser sites, the microglia of deficient mice displayed an activated, amoeboid morphology, with enlarged cell bodies, fewer branches, and shorter processes, the classic signature of inflammatory rather than surveillance-mode immune cells.

To prove that these effects stemmed from the immune cells themselves rather than some other tissue, the team turned to the myeloid-specific knockout. Deleting RORα only in the myeloid lineage reproduced the key findings: more fundus lesions at six, twelve, and beyond twelve months of age, larger lesion areas, increased subretinal accumulation of activated microglia, and elevated lipid droplet formation in immune cells of both young and aged animals. Laser-induced CNV lesions were larger in these mice as well, with 84 percent graded as leaky compared with 41 percent in floxed controls, and ex vivo choroidal explants from the knockout mice sprouted significantly more vessels, pointing to a pro-angiogenic shift driven by macrophages rather than by the vascular endothelium directly.

The mechanistic heart of the paper lies in what RORα does to PPARγ, a master regulator of fat uptake and storage. In RORα-deficient macrophages, retinas, and RPE/choroid tissue, Pparg mRNA and PPARγ protein were substantially upregulated, roughly doubling at the protein level. Chromatin immunoprecipitation experiments showed that RORα physically binds to a specific response element in the Pparg promoter, indicating that under normal conditions the receptor directly represses this lipogenic gene. When RORα is absent or pharmacologically inhibited with inverse agonists such as SR3335 and SR1001, PPARγ expression surges, lipid droplet formation increases roughly threefold, and macrophages take up more low-density lipoprotein. Exposure to 7-ketocholesterol, an oxidized cholesterol product that is a major component of drusen, further exaggerated lipid accumulation in the deficient cells, highlighting their heightened vulnerability to the very molecules that pile up in AMD eyes.

The lipid overload was not benign. RORα-deficient macrophages, retinas, and RPE/choroid samples showed elevated levels of the pro-inflammatory cytokines TNFα, IL-6, and IL-1β, along with reduced anti-inflammatory IL-10, and increased activation of NF-κB, the central inflammatory signaling pathway implicated in AMD. The deficient immune cells also lost expression of two migratory receptors, CX3CR1 and CD47, which are essential for macrophages and microglia to exit the subretinal space once their cleanup work is done. CD47 in particular is a known AMD risk factor that declines with age in humans. With these exit routes downregulated, the cells became trapped, proliferated more actively, migrated more aggressively in transwell assays, and produced more angiogenic factors including VEGF-A, VEGF-D, and angiopoietin-2. Conditioned medium from lipid-laden macrophages even stimulated the proliferation of human choroidal endothelial cells in culture, providing a direct functional link between macrophage fat overload and new blood vessel growth.

Perhaps most importantly for patients, the pathway proved druggable, at least in mice. When the researchers treated myeloid-specific knockout animals with T0070907, a selective PPARγ antagonist, before and during laser-induced CNV, lesion size shrank significantly, lipid droplet accumulation in retinal macrophages dropped markedly, and retinal expression of TNFα and IL-6 fell. This demonstrates that PPARγ acts as a key downstream effector of RORα signaling and that blocking it can partially reverse the damage caused by losing the receptor. In other words, the RORα–PPARγ axis offers a concrete therapeutic target: restoring RORα function or damping PPARγ activity could, in principle, restore lipid balance in retinal immune cells and cool the chronic inflammation that fuels neovascularization.

The findings arrive at a moment of growing translational momentum for RORα biology. A recent study showed that RORA-expressing gene therapy rescued retinal degeneration in a mouse model of Stargardt disease and dry AMD, and clinical trials evaluating RORA as a gene modifier therapy are currently underway for those conditions. The new work extends the receptor’s relevance to the wet, neovascular form of the disease and pinpoints the myeloid cell as the critical cellular mediator. There are caveats: the LysMCre system does not exclusively target microglia and shows incomplete recombination in that population, so the results reflect deletion in LysM-expressing myeloid cells broadly, and the human genetic association data for RORA and AMD risk have not been extensively updated by more recent studies. Still, the convergence of mouse genetics, pharmacology, chromatin biology, and human genetic association makes a compelling case that RORα sits at the junction of lipid metabolism and immune regulation in the aging retina.

What emerges is a coherent model of AMD pathogenesis in which a single nuclear receptor orchestrates an entire disease program. Under normal conditions, active RORα signaling keeps PPARγ in check, maintains lipid homeostasis in microglia and macrophages, supports the expression of migratory receptors that allow immune cells to leave the subretinal space, and restrains inflammatory cytokine production. When RORα is lost, whether through genetic variation, aging-related dysfunction, or the flood of oxidized cholesterol that characterizes the AMD eye, the system flips: PPARγ rises, immune cells gorge on lipids and become trapped, NF-κB-driven inflammation intensifies, and pro-angiogenic signals recruit the abnormal choroidal vessels that destroy central vision. If future therapies can reengage this axis in human patients, they may finally address one of the deepest roots of a disease that currently can only be managed, not prevented, at its immunometabolic source.

Subject of Research: Role of the nuclear receptor RORα in myeloid cell lipid metabolism, subretinal inflammation, and choroidal neovascularization in age-related macular degeneration

Article Title: Myeloid deficiency of RORα exacerbates lipid dysregulation and laser-induced choroidal neovascularization

Article References: Kushwah, N., Liu, C.-H., Bora, K., Maurya, M., Pavlovich, M. C., Fu, Z., Kamenecka, T. M., Sun, Y., Solt, L. A., & Chen, J. (2026). Myeloid deficiency of RORα exacerbates lipid dysregulation and laser-induced choroidal neovascularization. Angiogenesis, 29(4), Article 73. https://doi.org/10.1007/s10456-026-10092-2

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10092-2

Keywords: RORα, age-related macular degeneration, choroidal neovascularization, macrophages, microglia, PPARγ, lipid accumulation, inflammation, nuclear receptor, retina, drusen, NF-κB

Subretinal fibrosis is the body’s wound-healing response gone awry in the confined space between the retinal pigment epithelium and the photoreceptors. When abnormal choroidal blood vessels invade the subretinal space in neovascular AMD, bleeding, inflammation and vascular endothelial growth factor–driven remodeling follow. The retinal pigment epithelial (RPE) cells that normally act as quiet, polarized guardians of the photoreceptor layer respond by abandoning their identity: they lose tight junctions, reorganize their cytoskeleton, and transform into migratory, contractile, matrix-secreting cells. This process, epithelial-mesenchymal transition, or EMT, is driven centrally by transforming growth factor-beta (TGF-β) signaling and produces the collagen-rich scar that physically distorts and eventually destroys the overlying retina.

The research team, led by corresponding authors Chaoyang Zhang, Xiufeng Zhong, Haibin Tian and Jingfa Zhang, with first authors Xi Wang and Xueying Wang, reasoned that a molecule already known to suppress fibrosis in other organs could be repurposed for the eye. Sophocarpine has previously shown anti-fibrotic activity in hepatic and pulmonary models, and its alkaloid chemistry suggested a small molecule capable of crossing biological membranes and reaching intracellular targets. What remained entirely unknown was whether it could do anything for ocular fibrosis—and whether it could do so without harming the delicate neural retina it would have to coexist with.

The safety question came first, and the answer was reassuring. The investigators injected sophocarpine intravitreally into C57BL/6J mice at a concentration of 200 micromolar and then interrogated retinal function with electroretinography, a technique that measures the summed electrical responses of photoreceptors and inner retinal neurons to light flashes. Histological examination of the treated retinas found no detectable acute toxicity. That combination—a preserved electroretinographic waveform and an intact retinal architecture—is the basic license a compound needs before it can be considered seriously for intravitreal delivery, and many candidates never clear that bar.

With safety established, the team moved to a disease model that has become the standard for studying the fibrotic sequelae of neovascular AMD: laser-induced choroidal neovascularization. Focused laser burns to the mouse Bruch’s membrane trigger the growth of abnormal choroidal vessels into the subretinal space, followed by fibrotic scarring that closely mirrors the human lesion. When sophocarpine was delivered into the eyes of these mice, the CNV lesions shrank measurably, collagen deposition within the lesions decreased, and—critically—the co-localization of alpha-smooth muscle actin with RPE65, a marker of RPE cells that had acquired myofibroblast characteristics, was reduced. In plain terms, the RPE cells at the lesion edge were less inclined to become scar-forming cells.

The cellular mechanism was then dissected in culture using two complementary human RPE systems: the widely used ARPE-19 cell line and induced pluripotent stem cell–derived RPE cells, which recapitulate native RPE biology more faithfully. When these cells were stimulated with TGF-β1, they predictably ramped up the mesenchymal program: fibronectin, alpha-smooth muscle actin and vimentin all rose, while the tight-junction protein ZO-1, a hallmark of the healthy epithelial state, was lost. Sophocarpine treatment reversed this cascade. It suppressed the induction of fibronectin, α-SMA and vimentin, preserved ZO-1 expression, and curtailed the functional consequences of EMT—cell migration measured in wound-healing and Transwell assays, and the contractile behavior that scars use to wrinkle and detach the retina, captured in gel contraction assays. The findings were confirmed at transcript, protein and cellular localization levels using quantitative PCR, Western blotting and immunofluorescence.

The mechanistic heart of the paper lies in a striking signaling selectivity. TGF-β signals through two major intracellular routes: the canonical Smad pathway, in which Smad2 and Smad3 transcription factors are phosphorylated and carry the signal to the nucleus, and the non-canonical MAPK pathways, including the MEK/ERK cascade and p38 MAPK. Sophocarpine preferentially reduced the phosphorylation of MEK, ERK and p38 while leaving Smad2/3 phosphorylation untouched. This dissociation is significant because it suggests the compound does not blunt TGF-β signaling wholesale—which could interfere with the many homeostatic roles TGF-β plays in the eye—but instead specifically interrupts the MAPK arm that drives EMT-associated proliferation, migration and matrix production.

To probe how sophocarpine might achieve that selectivity at the molecular level, the team turned to computational structural biology. Molecular docking predicted that the alkaloid fits into binding pockets on MEK1, MEK2 and ERK2, the kinase pair that constitutes the canonical MAPK relay, and molecular dynamics simulations suggested the docked complexes remain stable over simulated time. These are predictive, not definitive, results—binding in silico must ultimately be validated with direct biophysical measurements and target-engagement assays in cells—but they furnish a concrete, testable hypothesis: that sophocarpine acts as a direct inhibitor of upstream MAPK kinases, thereby explaining both the reduced ERK and p38 phosphorylation and the suppression of the EMT program downstream.

The translational implications are considerable. Anti-VEGF therapy, the current mainstay for neovascular AMD, suppresses vascular leakage and growth but does nothing to stop the fibrovascular scar once it begins to organize; a substantial fraction of treated patients develop subretinal fibrosis and irreversible vision loss despite flushes of injections. A molecule that targets the fibrotic arm of the disease—by preserving RPE identity and restraining the TGF-β–MAPK–EMT axis—would address a therapeutic void that no approved drug currently fills. It would also be an unusually accessible candidate: sophocarpine is a defined small molecule with a long history of human exposure in herbal preparations, which could streamline preclinical development compared with entirely novel chemical entities.

That said, the distance from a laser-burn mouse and a culture dish to a clinic-ready therapy remains long. The study used a single dose level for the intravitreal safety assessment, relied on an acute injury model rather than spontaneous, slowly evolving human fibrosis, and its mechanistic target hypothesis awaits confirmation with techniques such as surface plasmon resonance and kinase assays. The authors themselves position sophocarpine as a promising preclinical candidate that warrants further investigation. Even so, the convergence of findings—in vivo reduction of scarring, in vitro reversal of EMT, and a coherent signaling rationale—makes this one of the more complete early-stage stories in ocular fibrosis research, and a reminder that some of ophthalmology’s next tools may still come from plants that traditional medicine has used for centuries.

Subject of Research: Therapeutic inhibition of subretinal fibrosis and retinal pigment epithelial EMT by the plant-derived alkaloid sophocarpine

Article Title: Sophocarpine, a bioactive alkaloid derived from Sophora flavescens, alleviates subretinal fibrosis by suppressing epithelial-mesenchymal transition

Article References: Sophocarpine, a bioactive alkaloid derived from Sophora flavescens, alleviates subretinal fibrosis by suppressing epithelial-mesenchymal transition. (n.d.). https://doi.org/10.1186/s12967-026-08995-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08995-1

Keywords: sophocarpine, Sophora flavescens, subretinal fibrosis, neovascular age-related macular degeneration, retinal pigment epithelium, epithelial-mesenchymal transition, TGF-beta, MEK/ERK, p38 MAPK, choroidal neovascularization, anti-fibrotic therapy, Journal of Translational Medicine

SCA7 belongs to a family of neurological diseases caused by expanded tracts of the three-letter DNA sequence CAG embedded within a gene. In this case the culprit is the ATXN7 gene on chromosome 3, which normally encodes a subunit of a protein complex called SAGA that regulates the transcription of thousands of other genes. When the CAG tract expands beyond a pathogenic threshold, typically more than 36 repeats, the resulting ataxin-7 protein carries an abnormally long polyglutamine segment. This stretched segment drives the protein to misfold and aggregate, poisoning neurons in the cerebellum, brainstem and, uniquely among the polyglutamine ataxias, the cone and rod photoreceptors of the retina. The landmark cloning of the SCA7 gene in 1997 revealed that the CAG expansion in this disorder is among the most unstable in the human genome, and that instability underlies a notorious genetic phenomenon called anticipation.

Anticipation means that each successive generation can inherit a longer repeat tract than the parent who transmitted it, and because longer repeats generally correlate with earlier onset and more severe disease, children of affected parents may fall ill decades before their parents did. Paternal transmission is classically associated with the most dramatic expansions, and maternally transmitted cases with massive somatic instability have produced infantile-onset disease. Yet repeat length is not the whole story. Studies in transgenic mice have shown that the genomic context surrounding the repeat strongly influences its instability, and clinical experience has repeatedly shown that patients carrying identical repeat lengths can manifest very different symptoms. The new report from Zhengzhou adds compelling human evidence to that murine and statistical picture, documenting how one family under a single roof can display markedly divergent phenotypes from one shared mutation.

The centerpiece of the report is an individual who, in addition to the expected cerebellar ataxia and retinal degeneration characteristic of SCA7, exhibited angioid streaks on fundus examination. Angioid streaks appear as irregular gray or dark red lines radiating from the optic disc, visible because calcified and fragmented Bruch’s membrane allows the underlying choroidal vasculature to show through. They are classically associated with pseudoxanthoma elasticum, Paget’s disease of bone, sickle cell hemoglobinopathies and certain rare metabolic conditions, but they have never been considered a feature of SCA7. The authors documented the streaks with multimodal ophthalmic imaging: color fundus photography captured the radiating lines, fundus autofluorescence revealed corresponding linear hypoautofluorescent changes, and optical coherence tomography showed focal irregularities at the junction of the retinal pigment epithelium and Bruch’s membrane. The convergence of findings across these independent modalities strengthens the case that the structural abnormality was real and not an imaging artifact.

The clinical significance of this observation is twofold. First, angioid streaks are clinically dangerous in their own right because the brittle Bruch’s membrane predisposes patients to choroidal neovascularization, the abnormal ingrowth of fragile blood vessels that can hemorrhage and cause abrupt, severe central vision loss. A recent comprehensive review of angioid streak-related choroidal neovascularization emphasized that early detection and prompt anti-VEGF treatment can preserve vision in these patients. If SCA7 patients can develop angioid streaks, ophthalmologists caring for them may need to add this complication to their surveillance list, distinguishing new vessel growth from the slower cone-rod retinal dystrophy that ordinarily accompanies the disease. Second, from a mechanistic standpoint, the finding raises the question of whether mutant ataxin-7, which is expressed outside the nervous system, might directly or indirectly compromise Bruch’s membrane integrity, or whether the association is coincidental and merely co-occurring in this individual. The authors are appropriately cautious, presenting the case as an expansion of the phenotypic spectrum rather than proof of causation.

Equally instructive is the intrafamilial variability the report documents. A second affected individual in the same kindred showed advanced retinal degeneration with no identifiable angioid streaks at all: fundus photographs revealed diffuse degenerative changes, autofluorescence demonstrated widespread hypoautofluorescence, and OCT confirmed disruption and thinning of the outer retinal layers and retinal pigment epithelium. Two relatives, one mutation, one family environment, and yet two visibly distinct retinal phenotypes. This kind of divergence within a single pedigree is a vivid demonstration that genotype alone does not determine phenotype. Candidate modifiers include the exact repeat length and its somatic instability in different tissues, other genetic variants inherited independently at modifier loci, epigenetic differences, sex, environmental exposures and stochastic developmental events. Longitudinal cohort studies of related ataxias such as SCA1, SCA2, SCA3 and SCA6 have similarly shown that progression rates vary widely even after accounting for repeat length, and recent work on SCA1 has even uncovered sex-specific differences in presentation and progression, reinforcing the growing recognition that hereditary ataxias are shaped by networks of modifiers rather than by a single number in a sequencing report.

For clinicians, the practical message is that SCA7 should be considered a moving target. The disease has already been reported masquerading as Stargardt’s disease, an inherited juvenile macular degeneration, in patients who presented with vision loss before ataxia appeared. Some patients receive their first diagnosis from an ophthalmologist rather than a neurologist because the retina fails before balance does. Adding angioid streaks to the differential expands the diagnostic considerations in both directions: neurologists evaluating a patient with unexplained ataxia who happens to have angioid streaks on fundoscopy may now reasonably order ATXN7 repeat testing, and ophthalmologists encountering angioid streaks of uncertain cause should be alert to subtle cerebellar signs. Genetic testing remains the only definitive diagnostic tool, and the report underscores the value of combining neurological assessment, genetic confirmation and multimodal ophthalmic imaging in the workup of suspected hereditary ataxias.

The molecular biology underlying SCA7 continues to be an active therapeutic frontier. Because the disease is caused by a toxic gain of function from the expanded protein, strategies under investigation include antisense oligonucleotides designed to reduce ataxin-7 production, RNA interference approaches, gene editing to trim the repeat tract, and small molecules aimed at stabilizing the transcriptional machinery that mutant ataxin-7 disrupts. Understanding the full range of tissues affected matters for these efforts. If retinal structures beyond photoreceptors, such as Bruch’s membrane and the retinal pigment epithelium, can be drawn into the disease process, then delivery of any future therapy must reach not only cerebellar neurons but also the posterior segment of the eye, a compartment with its own pharmacological barriers. Detailed phenotyping of rare cases, as performed here, helps define the true therapeutic target list.

The study itself was a modest but careful piece of clinical science. Conducted at a single center in Zhengzhou with funding from Henan provincial research programs, it involved detailed collection and integration of clinical, genetic and imaging data, with all participants or their legal guardians providing written informed consent and the protocol approved under the Declaration of Helsinki. The authors, Chunyan Cao, Shang Xu, Yaqiong Li and Jiewen Zhang, conceived the study, assembled the data and interpreted the findings collaboratively, and they acknowledge that the observations require replication in larger cohorts before the association can be considered established. Data supporting the findings are available from the corresponding author upon reasonable request.

Rare observations like these are often dismissed as curiosities, yet history shows that they can redefine how diseases are understood and detected. Every expanded phenotypic spectrum shortens the diagnostic odyssey for someone, because a physician who has read that SCA7 can produce angioid streaks will think to test for it sooner. Every documented instance of intrafamilial variability strengthens the scientific case for hunting genetic modifiers, which in turn may reveal new therapeutic targets applicable beyond the rare families in which they are found. As gene-based therapies for polyglutamine disorders edge closer to the clinic, the precision with which the medical community can recognize every face these diseases present becomes not merely an academic exercise but a prerequisite for treating patients early enough to matter. This single family in Henan Province, examined with modern genetics and multimodal retinal imaging, has added one more facet to that recognition effort, and it is a reminder that even the best-characterized Mendelian diseases still hold surprises.

Subject of Research: Phenotypic expansion of spinocerebellar ataxia type 7, including angioid streaks and intrafamilial clinical variability

Article Title: Expanding the phenotypic spectrum of spinocerebellar ataxia type 7: angioid streaks and intrafamilial phenotypic variability

Article References: Cao, C., Xu, S., Li, Y., & Zhang, J. (2026). Expanding the phenotypic spectrum of spinocerebellar ataxia type 7: angioid streaks and intrafamilial phenotypic variability. Journal of Neurology, 273(10), Article 589. https://doi.org/10.1007/s00415-026-14081-9

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14081-9

Keywords: spinocerebellar ataxia type 7, ATXN7, CAG repeat expansion, angioid streaks, phenotypic variability, retinal degeneration, cone-rod dystrophy, Bruch's membrane, genetic anticipation, hereditary ataxia, multimodal retinal imaging, choroidal neovascularization